@thesis{thesis,
		author={Tri  Suryani},
		title ={GAMBARAN PEMBERIAN HEPATOPROTEKTOR
TERHADAP PERUBAHAN KADAR SGOT/SGPT
PADA PASIEN HEPATITIS IMBAS OAT
DI RSUD KAB. KARANGANYAR},
		year={2020},
		url={http://librepo.stikesnas.ac.id/448/},
		abstract={Tuberculosis is an infectious disease caused by the bacteria
Mycobacterium tuberculosis. Although Anti-Hepatitis drugs have a
bactericidal and bacteriostatic ability against Mycobacterium tuberculosis,
Anti-Hepatitis drugs also causes side effects, one of which is hepatitis because
it uses Anti-Hepatitis drugs. This study discusses hepatitis B in tuberculosis
patients in RSUD Kab. Karanganyar in 2019. This research is a descriptive
study with retrospective purposes. The study subjects received 69 tuberculosis
patients who received inpatient or outpatient Anti-Hepatitis drugs. This study
was conducted by observing patient characteristics including sex, age,
elevated levels of SGPT and severity of hepatitis due to using Anti-Hepatitis
drugs. The results showed that as many as 36 male patients (52.2%) and 33
female patients (47.8%) suffered from tuberculosis with the most age range,
namely 46-55 years (34.8%). There were 34 patients (49.3%) who suffered
from hepatitis due to using Anti-Hepatitis drugs and were divided into 3
categories, namely the normal category of 27 patients (79.4%), stage 1 of 5
people (14.7%) and stage 2 of 2 patients (5.9%). The conclusion of this
research is Temulawak (Curcuma xanthorriza Roxb) can be used as a
hepatoprotector so that it can reduce levels of SGOT and SGPT in patients.
Based on the stage of severity of respondents who experienced OAT-induced
hepatitis from 34 patients (49.3%), it was categorized into three categories: 27
patients (79.4%) in normal category, 5 in Stadium 1 (14.7%), 2 in Stadium 2
(5.9%) ).}
		}